# Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas

> **NCT07066982** · PHASE1,PHASE2 · RECRUITING · sponsor: **Essen Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Sarcoma
- Sarcoma, Kaposi
- Sarcoma, Ewing
- Sarcoma,Soft Tissue
- Sarcoma of Bone and Connective Tissue
- Sarcoma, Synovial
- Sarcoma Metastatic
- Sarcomas, Germinoblastic
- Sarcoma of Bone

## Interventions

- **BIOLOGICAL:** CD146/HER2 CAR-T cells

## Key facts

- **NCT ID:** NCT07066982
- **Lead sponsor:** Essen Biotech
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2027-12-10
- **Final completion:** 2028-12-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07066982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07066982, "Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07066982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*